Browse FRAS1

Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location Cell membrane Single-pass type I membrane protein Extracellular side
Domain PF03160 Calx-beta domain
PF00093 von Willebrand factor type C domain
Function

-

> Gene Ontology
 
Biological Process GO:0001655 urogenital system development
GO:0001656 metanephros development
GO:0001822 kidney development
GO:0003338 metanephros morphogenesis
GO:0030326 embryonic limb morphogenesis
GO:0035107 appendage morphogenesis
GO:0035108 limb morphogenesis
GO:0035113 embryonic appendage morphogenesis
GO:0043588 skin development
GO:0048736 appendage development
GO:0060021 palate development
GO:0060173 limb development
GO:0060993 kidney morphogenesis
GO:0072001 renal system development
Molecular Function -
Cellular Component GO:0005578 proteinaceous extracellular matrix
GO:0005604 basement membrane
GO:0044420 extracellular matrix component
GO:0061618 sublamina densa
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between FRAS1 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.

Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of FRAS1 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of FRAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-0.0980.779
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-0.0390.947
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.1360.787
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 9161.0340.0486
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 591.310.547
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 470.6870.803
729033130MelanomaallAnti-PD-1 (nivolumab) 26230.4620.464
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 15110.8290.449
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.1320.907
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.1650.885
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.5520.711
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.1740.459
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of FRAS1 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14177.15.91.21
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 103100101
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 41407.1-7.11
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 27733.712.3-8.60.28
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 27593.715.3-11.60.161
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)211738.129.48.70.734
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)8637.516.720.80.58
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)131138.536.42.11
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 91611.125-13.90.621
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59044.4-44.40.221
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47250250.364
1329033130MelanomaallAnti-PD-1 (nivolumab) 382715.83.712.10.224
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 221313.6013.60.279
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 161418.87.111.70.602
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of FRAS1. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of FRAS1. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by FRAS1.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of FRAS1. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of FRAS1 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between FRAS1 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolFRAS1
NameFraser extracellular matrix complex subunit 1
Aliases FLJ22031; FLJ14927; KIAA1500; Fraser syndrome 1; Extracellular matrix protein FRAS1
Chromosomal Location4q21.21
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting FRAS1 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.